An overview of bacillus anthracis bacteria, one of the most important biological agents

Maryam Najafi Asl, Amin Jaydari, Nemat Shams, Peyman Khademi

Abstract


So far, more than 1400 human pathogens have been identified. Of this number, more than 60% have a common origin between humans and animals, which infect humans through animal reservoirs. These diseases include viruses such as influenza, less common (but fatal) diseases such as rabies, and neglected parasites such as echinococcosis and cysticercosis. The subcategory of bacterial zoonoses also varies, with pathogens common in industrial settings (including salmonella and bartonella henselae, the causative agent of cat-scratch disease) and diseases more associated with impoverished tropical regions (such as melioidosis and leptospirosis). In this article, we will examine the bacillus anthracis bacteria that causes anthrax, which is one of the most important bacteria (the cause of zoonotic diseases) and is also considered one of the agents of bioterrorism.


Keywords


zoonoses diseases; anthrax; bioterrorism

Full Text:

PDF

References


[1]Taylor LH, Latham SM, woolhouse MEJ. Risk factors for human disease emergence. Woolhouse MEJ, Dye C, eds. Philosophical Transactions of the Royal Society of London Series B: Biological Sciences. 2001; 356(1411): 983-989. doi: 10.1098/rstb.2001.0888

[2]Barras V, Greub G. History of biological warfare and bioterrorism. Clinical Microbiology and Infection. 2014; 20(6): 497-502. doi: 10.1111/1469-0691.12706

[3]Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk Anthrax Outbreak of 1979. Science. 1994; 266(5188): 1202-1208. doi: 10.1126/science.7973702

[4]Jaton K, Greub G. Clinical microbiologists facing an anthrax alert. Clinical Microbiology and Infection. 2014; 20(6): 503-506. doi: 10.1111/1469-0691.12682

[5]Vieira AR, Salzer JS, Traxler RM, et al. Enhancing Surveillance and Diagnostics in Anthrax-Endemic Countries. Emerging Infectious Diseases. 2017; 23(13). doi: 10.3201/eid2313.170431

[6]Bush LM, Abrams BH, Beall A, et al. Index Case of Fatal Inhalational Anthrax Due to Bioterrorism in the United States. New England Journal of Medicine. 2001; 345(22): 1607-1610. doi: 10.1056/nejmoa012948

[7]Hughes JM, Gerberding JL. Anthrax Bioterrorism: Lessons Learned and Future Directions. Emerging Infectious Diseases. 2002; 8(10): 1013-1014. doi: 10.3201/eid0810.020466

[8]Friebe S, Van der Goot F, Bürgi J. The Ins and Outs of Anthrax Toxin. Toxins. 2016; 8(3): 69. doi: 10.3390/toxins8030069

[9]Adalja AA, Toner E, Inglesby TV. Clinical Management of Potential Bioterrorism-Related Conditions. Longo DL, ed. New England Journal of Medicine. 2015; 372(10): 954-962. doi: 10.1056/nejmra1409755

[10]Shafazand S. When bioterrorism strikes: diagnosis and management of inhalational anthrax. Seminars in Respiratory Infections. 2003; 18: 134-145.

[11]Doganay M, Metan G, Alp E. A review of cutaneous anthrax and its outcome. Journal of Infection and Public Health. 2010; 3(3): 98-105. doi: 10.1016/j.jiph.2010.07.004

[12]Sirisanthana T, Brown AE. Anthrax of the Gastrointestinal Tract. Emerging Infectious Diseases. 2002; 8(7): 649-651. doi: 10.3201/eid0807.020062

[13]Purcell B, Worsham P, Friedlander A. Anthrax. In: Dembek ZS (editor). Medical aspects of biological warfare. Falls Church, VA: Borden Institute and US Army Office of the Surgeon General; 2007.

[14]Barakat LA. Fatal Inhalational Anthrax in a 94-Year-Old Connecticut Woman. JAMA. 2002; 287(7): 863. doi: 10.1001/jama.287.7.863

[15]Abramova FA, Grinberg LM, Yampolskaya OV, et al. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proceedings of the National Academy of Sciences. 1993; 90(6): 2291-2294. doi: 10.1073/pnas.90.6.2291

[16]Bower WA, Hendricks K, Pillai S, et al. Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident. MMWR Recommendations and Reports. 2015; 64(4): 1-22. doi: 10.15585/mmwr.rr6404a1

[17]Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults. Emerging Infectious Diseases. 2014; 20(2). doi: 10.3201/eid2002.130687

[18]Katharios-Lanwermeyer S, Holty JE, Person M, et al. Identifying Meningitis During an Anthrax Mass Casualty Incident: Systematic Review of Systemic Anthrax Since 1880. Clinical Infectious Diseases. 2016; 62(12): 1537-1545. doi: 10.1093/cid/ciw184

[19]Meaney-Delman D, Zotti ME, Creanga AA, et al. Special Considerations for Prophylaxis for and Treatment of Anthrax in Pregnant and Postpartum Women. Emerging Infectious Diseases. 2014; 20(2). doi: 10.3201/eid2002.130611

[20]Walsh JJ, Pesik N, Quinn CP, et al. A Case of Naturally Acquired Inhalation Anthrax: Clinical Care and Analyses of Anti-Protective Antigen Immunoglobulin G and Lethal Factor. Clinical Infectious Diseases. 2007; 44(7): 968-971. doi: 10.1086/512372

[21]Webster JI, Moayeri M, Sternberg EM. Novel Repression of the Glucocorticoid Receptor by Anthrax Lethal Toxin. Annals of the New York Academy of Sciences. 2004; 1024(1): 9-23. doi: 10.1196/annals.1321.003

[22]Inglesby TV, O’Toole T, Henderson DA, et al. Anthrax as a Biological Weapon, 2002. JAMA. 2002; 287(17): 2236. doi: 10.1001/jama.287.17.2236

[23]Yamamoto BJ, Shadiack AM, Carpenter S, et al. Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity. Antimicrobial Agents and Chemotherapy. 2016; 60(10): 5787-5795. doi: 10.1128/aac.00972-16

[24]Yamamoto BJ, Shadiack AM, Carpenter S, et al. Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax. Antimicrobial Agents and Chemotherapy. 2016; 60(10): 5796-5805. doi: 10.1128/aac.01102-16

[25]Migone TS, Bolmer S, Zhong J, et al. Added Benefit of Raxibacumab to Antibiotic Treatment of Inhalational Anthrax. Antimicrobial Agents and Chemotherapy. 2015; 59(2): 1145-1151. doi: 10.1128/aac.04606-14

[26]Kummerfeldt C. Raxibacumab: potential role in the treatment of inhalational anthrax. Infection and Drug Resistance. Published online April 2014: 101. doi: 10.2147/idr.s47305

[27]Kammanadiminti S, Patnaikuni RK, Comer J, et al. Combination Therapy with Antibiotics and Anthrax Immune Globulin Intravenous (AIGIV) Is Potentially More Effective than Antibiotics Alone in Rabbit Model of Inhalational Anthrax. PLoS ONE. 2014; 9(9): e106393. doi: 10.1371/journal.pone.0106393




DOI: https://doi.org/10.18686/pas.v5i1.2227

Refbacks

  • There are currently no refbacks.
Copyright © 2020 Universe Scientific Publishing. All rights reserved.